Akebia Therapeutics, Inc. 8-K

What Happened

• Akebia Therapeutics, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025 and provided business highlights on February 26, 2026. The company highlighted progress related to the commercial launch of Vafseo® (vadadustat) and updates on its development pipeline. The announcement was issued as a press release furnished as Exhibit 99.1 to the Form 8-K.

Key Details

• Press release date: February 26, 2026; reporting results for the period ended December 31, 2025.
• Topic focus: fourth-quarter and full-year 2025 financial results plus recent business highlights tied to the commercial launch of Vafseo (vadadustat) and pipeline progress.
• The press release is furnished as Exhibit 99.1 to the Form 8-K (not filed).
• Form 8-K was signed by President & CEO John P. Butler.

Why It Matters

• Quarterly and full-year results give investors current visibility into Akebia’s financial performance and trends following the Vafseo commercial launch.
• Updates on Vafseo’s commercial rollout and the company’s pipeline are key to assessing near-term revenue potential and future growth drivers.
• Investors should review the furnished press release (Exhibit 99.1) for detailed revenue, expense, guidance, and commercial metrics disclosed by the company.